Our monthly newsletter reports on the patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from April 2020, including:
- The Federal Circuit potentially extends the potential reach chemical compound structural similarity obviousness law
- The Federal Circuit holds that a section 156 patent term extension based on FDA approval of an active ingredient “does not encompass a metabolite of the active ingredient”
- The Federal Circuit issues two decisions on Article III standing in appeals from the PTAB.
